International Cancer Patient Coalition

Colombia

Breast Cancer Factsheet: Insights & Key Developments

Key Insights on Breast Cancer Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Breast Cancer Screening

Breast cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping breast cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- Breast cancer incidence: 31.2% of all female cancers
- Incidence rate: 48.3 per 100,000 per year
- Total cases (2018-2022): 39,750 reported cases
- Ethnic distribution: Mestizo (70.5%), Afro-Colombian (16.3%), Indigenous (4.8%), Other (8.4%)
- Lifetime risk in Colombia: 1 in 18 women
- Daily diagnoses (2018-2022): Approximately 22 women per day
- Breast cancer deaths (2018-2022): ~14.6% of total cases
- 5-year survival rate: ~81% (varies by stage)
- Stage I diagnosis increase: 29% (2008-2012) → 45% (2018-2022)
- Young women cases: 16.7% under 45 years old
- Most affected age group: 50-59 years
- Mammogram detection: 38% via screening programs
- Screening participation (ages 50-69): Only 34%

International Cancer Patient Coalition

Colombia

Infrastructure



Strengths

- HER2, ER, and PR testing available in urban centers.
- Integration of molecular diagnostics into treatment planning is growing.

Weakness

- Specialized cancer services concentrated in Bogotá, Medellín, and Cali.
- BRCA testing under 30% due to cost and low public reimbursement.

S W O T

Opportunity

- Expand precision oncology beyond major cities.
- Improve lab infrastructure and NGS availability in public sector.

Threats

- Delayed diagnosis and treatment in rural areas.
- Financial and logistical barriers to biomarker expansion.

5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.

4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.

3. Moderate infrastructure, primarily in private settings or research institutions.

2. Limited infrastructure, available only in select centers or for high-cost private testing.

1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	3	3
Kenya	2	2
Nigeria	2	2
Egypt	3	3
Morocco	2	2
Algeria	2	2
Ethiopia	1	1
India	3	3
Japan	4	4
South Korea	4	4
China	3	3
Thailand	3	3
Singapore	4	4
United Kingdom	4	4
Germany	5	5
France	4	4
Netherlands	5	5
Sweden	5	5
Italy	4	4
Spain	4	4
Poland	3	3
Mexico	2	2
Brazil	3	3
Argentina	3	3
Chile	3	3
Colombia	2	2
United States	5	5
Canada	5	5
Australia	4	4
New Zealand	4	4
Greece	3	3
Rwanda	1	1
Uganda	1	1
Serbia	3	3
Saudi Arabia	3	3
UAE	3	4
Syria	1	1
Indonesia	2	2
Vietnam	2	2
Philippines	2	2
Russia	4	3

International Cancer Patient Coalition

Colombia

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Public EPS system provides basic coverage for treatments.
- Awareness efforts have improved screening participation to ~55%.

Weakness

- Wait times >3 months for treatment in public system.
- Research funding <5% dedicated to breast cancer.

S W O T

Opportunity

- Expand nonprofit-driven education and advocacy efforts.
- Increase investment in locally relevant clinical trials.

Threats

- High private-sector costs create access inequities.
- Delayed approvals and long wait times hinder timely care.

5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.

4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.

3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.

2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.

1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	3	3	3
Kenya	2	2	2
Nigeria	2	2	2
Egypt	3	3	3
Morocco	2	2	3
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	4
South Korea	4	4	4
China	3	4	3
Thailand	3	3	3
Singapore	4	5	5
United Kingdom	4	5	5
Germany	5	5	5
France	4	5	5
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	2	3
Brazil	3	3	3
Argentina	3	3	3
Chile	2	3	3
Colombia	2	2	3
United States	5	5	5
Canada	5	5	5
Australia	4	4	5
New Zealand	4	4	4
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	3	3	3
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	2	1	1
Indonesia	3	2	3
Vietnam	3	2	3
Philippines	3	2	3
Russia	4	4	3

International Cancer Patient Coalition

Colombia

Survival Rates, Early Detection and Palliative Care



Strengths

- Participation in mammography screening is improving.
- Palliative care available in major hospitals.

Weakness

- 40% of diagnoses still occur at Stage III or IV.
- Rural areas lack adequate palliative services and screening access.

S W O T

Opportunity

- Strengthen screening infrastructure with mobile units.
- Expand pain management and palliative programs to public hospitals.

Threats

- Geographic and socioeconomic disparities threaten survival outcomes.
- Delayed detection undermines treatment success.

5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.

4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.

3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.

2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.

1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	3	3	3
Kenya	2	2	2
Nigeria	2	1	2
Egypt	3	3	3
Morocco	3	3	3
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	4
South Korea	4	4	4
China	3	3	3
Thailand	3	3	3
Singapore	4	5	4
United Kingdom	4	5	4
Germany	5	5	5
France	4	5	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	3	2
Brazil	3	3	3
Argentina	3	3	3
Chile	2	3	3
Colombia	2	3	2
United States	5	5	5
Canada	5	5	4
Australia	4	4	4
New Zealand	4	4	4
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	3	3	3
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	2	2	1
Indonesia	3	3	2
Vietnam	3	3	2
Philippines	3	3	3
Russia	4	3	3

International Cancer Patient Coalition

Colombia

Utilization of Biomarkers



Strengths

- HER2/ER/PR testing routine in major urban hospitals.
- NGS and genomic profiling available in private institutions.

Weakness

- BRCA testing coverage <25% due to financial barriers.
- Delays in test results in public facilities impact decision-making.

S W O T

Opportunity

- Increase public funding for BRCA and NGS testing.
- Expand biomarker use through public-private partnerships.

Threats

- Lack of reimbursement perpetuates inequality in biomarker access.
- Limited integration of genomic testing in national guidelines.

5. 80% Biomarker testing is widely available and routinely performed as part of standard clinical practice. Strong integration into treatment decisions, with national coverage and reimbursement ensuring accessibility.

4. 61-80%. Biomarker testing is commonly used, but access may be limited in certain regions or patient groups. Some disparities exist in coverage or affordability, but it is still a crucial part of cancer diagnostics

3. 41-60% Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.

2. 20-40% Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.

1. <20% Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



International Cancer Patient Coalition

Colombia

Clinical Guidelines



Strengths

- National guidelines align with ESMO and NCCN standards.
- Adoption strong in top-tier centers with access to training.

Weakness

- Implementation varies between private and public sectors.
- Guideline updates slow to reach rural and under-resourced hospitals.

S W O T

Opportunity

- Offer digital CME and centralized training platforms.
- Ensure wider distribution of up-to-date guidelines.

Threats

- Fragmented implementation creates care inconsistencies.
- Limited staff and funding in public hospitals hinder integration.

	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	✖	✖	O	✖	✖
Feasibility of Integration	✖	✖	O	✖	✖
Adoption of International Guidelines	✖	✖	O	✖	✖
Engagement with Updates	✖	✖	✖	O	✖
ESMO Guidelines Implementation	✖	✖	O	✖	✖

International Cancer Patient Coalition

Colombia

Reimbursement

Strengths

- National health insurance (EPS) covers standard treatments.
- PBS ensures baseline access to surgery, chemo, and radiotherapy.

Weakness

- Delays of >3 months common for public reimbursement approvals.
- Targeted therapies often not covered or require legal appeals.

Opportunity

- Streamline approval processes for diagnostics and novel therapies.
- Improve BRCA and biomarker coverage in public plans.

Threats

- Out-of-pocket costs up to $4,000/month limit treatment access.
- Inequitable access due to fragmented reimbursement.

O A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.

O A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.

✖ No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement	No-cost Access
South Africa	O	✖
Kenya	✖	✖
Nigeria	✖	✖
Egypt	O	O
Morocco	O	✖
Algeria	O	✖
Ethiopia	✖	✖
India	O	✖
Japan	O	O
South Korea	O	O
China	O	O
Thailand	O	O
Singapore	O	O
United Kingdom	O	O
Germany	O	O
France	O	O
Netherlands	O	O
Sweden	O	O
Italy	O	O
Spain	O	O
Poland	O	O
Mexico	O	✖
Brazil	O	✖
Argentina	O	✖
Chile	O	O
Colombia	O	✖
United States	O	O
Canada	O	O
Australia	O	O
New Zealand	O	O
Greece	O	O
Rwanda	✖	✖
Uganda	✖	✖
Serbia	O	O
Saudi Arabia	O	O
UAE	O	O
Syria	O	O
Indonesia	O	O
Vietnam	✖	✖
Philippines	✖	✖
Russia	O	O

International Cancer Patient Coalition

Colombia

Breast Cancer Screening

Strengths

- National program recommends biennial mammograms for women 50–69.
- Urban screening rates improving due to public campaigns.

Weakness

- Only 55–60% of eligible women screened; rural rates lower.
- Wait times for mammograms can exceed 6 months.



Opportunity

- Deploy mobile units and outreach in rural/underserved zones.
- Improve follow-up and diagnostics via public education.

Threats

- Regional disparities could worsen late-stage diagnosis rates.
- High uninsured population faces barriers to consistent screening.

Country	Breast Cancer Screening
United States	Biennial mammograms (50-74 years)
United Kingdom	Triennial mammograms (50-71 years)
Canada	Mammograms every 2-3 years (50-74 years)
Australia	Biennial mammograms (50-74 years)
Germany	Mammograms every 2 years (50-69 years)
France	Biennial mammograms (50-74 years)
Netherlands	Mammograms every 2 years (50-75 years)
Sweden	Mammograms every 18-24 months (40-74 years)
Italy	Mammograms every 2 years (50-69 years)
Spain	Mammograms every 2 years (50-69 years)
Poland	Mammograms every 2 years (50-69 years)
Japan	Mammograms every 2 years (40+ years)
South Korea	Biennial mammograms (40+ years)
China	Regional mammogram programs (40-69 years)
India	Opportunistic screening
Singapore	Biennial mammograms (50-69 years)
Saudi Arabia	Opportunistic screening; regional programs for women aged 40+
UAE	Opportunistic screening; encouraged every 2 years for 40-69 years
Syria	No national program; limited local initiatives due to conflict

Country	Breast Cancer Screening
Thailand	Biennial mammograms (50-69 years)
South Africa	Opportunistic screening
Kenya	No national program
Nigeria	No national program
Egypt	National awareness campaigns
Morocco	National program for 45-69 years
Algeria	Planned national program (50-69 years)
Ethiopia	No national program
Mexico	Biennial mammograms (40-69 years)
Brazil	Biennial mammograms (50-69 years)
Argentina	Biennial mammograms (50-69 years)
Chile	Mammograms every 3 years (50-69 years)
Colombia	Biennial mammograms (50-69 years)
New Zealand	Biennial mammograms (45-69 years)
Greece	Biennial mammograms (50-69 years)
Rwanda	No national program
Uganda	No national program
Serbia	Biennial mammograms (50-69 years)
Indonesia	Opportunistic screening; no national mammography program
Vietnam	Regional mammography programs; pilot programs in urban areas (age 45–69)
Philippines	Opportunistic screening; mammography recommended every 2 years for women 50+
Russia	National program for biennial mammograms (50–69 years)